{
    "Case ID": "080457",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and infringement"
    ],
    "Legal_Issue": [
        "Validity of Novartis's patent on EXJADE under Canadian law"
    ],
    "Governing_Law": [
        "Canadian Patent Act"
    ],
    "Procedural_Stage": [
        "Federal Court litigation"
    ],
    "Evidence_Assessment": [
        "Expert testimonies were considered; utility, obviousness, and sufficiency evaluated"
    ],
    "Decision_Outcome": [
        "Compound claims upheld as valid; use claims found lacking demonstrated utility"
    ],
    "Burden_of_Proof": [
        "On Teva to prove invalidity of the patent"
    ],
    "Credibility_Factor": [
        "Court relied on expert evidence and technical analysis"
    ],
    "Legal_Rule": [
        "Patent must demonstrate utility, non-obviousness, and sufficient disclosure"
    ],
    "Standard_of_Review": [
        "Balance of probabilities in civil proceeding"
    ],
    "Procedural_Issue": [
        "Application for prohibition of Notice of Compliance to generic manufacturer"
    ],
    "Grounds_for_Claim": [
        "Inutility, obviousness, insufficiency"
    ],
    "Outcome_on_Merits": [
        "Novartis succeeded on compound claims; Teva barred from market entry until patent expiry"
    ],
    "Decision_Maker": [
        "Federal Court of Canada"
    ],
    "Judicial_Review_Outcome": [
        "Not applicable â€“ first instance decision"
    ],
    "Review_Standard": [
        "Statutory interpretation and application of patent law principles"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing provided with opportunity to present evidence"
    ],
    "Key_Evidence_Considered": [
        "Scientific data on efficacy, prior art compounds, disclosure in patent specification"
    ],
    "Legal_Framework": [
        "Canadian intellectual property and patent law"
    ],
    "Applicant_Challenge": [
        "Novartis challenged Teva's allegations of patent invalidity"
    ],
    "Court_Result": [
        "Patent upheld for compound claims; injunction granted against Teva"
    ],
    "Legal_Rule_Source": [
        "Canadian Patent Act and case law"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence (civil standard)"
    ],
    "Defendant_Response": [
        "Teva alleged inutility, obviousness, and insufficiency of the patent"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert testimony, prior art references"
    ],
    "Remedy_Requested": [
        "Prohibition of Notice of Compliance to Teva"
    ],
    "Outcome": [
        "Remedy granted; Teva prohibited from obtaining NOC"
    ],
    "Decision_Authority": [
        "Federal Court"
    ],
    "Remedy_Sought": [
        "Market exclusivity protection through injunction"
    ],
    "Resolution_Mechanism": [
        "Judicial determination"
    ],
    "Legal_Provision": [
        "Sections 2, 27, 28.2, 53, 64 of the Canadian Patent Act"
    ],
    "Authority": [
        "Federal Court of Canada"
    ],
    "Claimant_Status": [
        "Patent holder (Novartis)"
    ],
    "Legal_Provision_Cited": [
        "Utility (s. 2), Non-obviousness (s. 28.3), Sufficiency (s. 27)"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Invalidity due to inutility, obviousness, insufficiency"
    ],
    "Applicable_Process": [
        "Regulatory approval process under Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Outcome_of_Review": [
        "Patent upheld in part; use claims invalidated, compound claims valid"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition decision under PM(NOC) Regulations"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Canadian Patent Law requirements for valid patent"
    ]
}